ArticleJournal of clinical hypertension (Greenwich, Conn.)2013
Masked hypertension and atherogenesis: the impact of apelin and relaxin plasma levels.
Article in Journal of clinical hypertension (Greenwich, Conn.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 45 citations in OpenAlex.
- Treatment-associated change in apelin concentration in patients with hypertension and its relationship with left ventricular diastolic function.Anatolian journal of cardiology · 2017Trial
- Vascular imbalance in polycystic ovary syndrome: Insights into endothelial dysfunction.PloS one · 2025Article
- Significance of plasma relaxin-2 levels in patients with primary hypertension and type 2 diabetes mellitus.Wiener medizinische Wochenschrift (1946) · 2024Article
- Relaxin-2 as a Potential Biomarker in Cardiovascular Diseases.Journal of personalized medicine · 2022Review
- Apelin, Omentin-1, and Vaspin in patients with essential hypertension: association of adipokines with trace elements, inflammatory cytokines, and oxidative damage markers.Irish journal of medical science · 2021Article
- Epidemiological Impact and Clinical Consequences of Masked Hypertension: A Narrative Review.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2020Review
- Apelin/APJ system: A potential therapeutic target for endothelial dysfunction-related diseases.Journal of cellular physiology · 2019Review
- The impact of apelin and relaxin plasma levels in masked hypertension and white coat hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2019Article
- Associations between serum relaxin 2, aneurysm formation/size and severity of atherosclerosis: a preliminary prospective analysis.Acta pharmacologica Sinica · 2018Article
- Apelin and Atrial Fibrillation: The Role in the Arrhythmia Recurrence Prognosis.Disease markers · 2018Observational
- RXFP1 Receptor Activation by Relaxin-2 Induces Vascular Relaxation in MiceFrontiers in physiology · 2018Article
- Higher Frequency of Nocturnal Blood Pressure Dipping but Not Heart Rate Dipping in Inflammatory Bowel Disease.Digestive diseases and sciences · 2017Article
- Prevalence of masked hypertension in African Americans.Journal of clinical hypertension (Greenwich, Conn.) · 2014Article
- Apelin/APJ system: a promising therapy target for hypertension.Molecular biology reports · 2014Review
- Participation of hypertension patients in early-phase clinical trials.Journal of clinical hypertension (Greenwich, Conn.) · 2014Article
- Apelin and relaxin plasma levels in young healthy offspring of patients with essential hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2014Article
- Inflammatory markers should be assessed together with cardiovascular risk factors by clinicians in masked hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2013Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent evidence demonstrates that masked hypertension (MH) is a significant predictor of cardiovascular disease, while apelin and relaxin are two novel factors with a significant role in vascular regulation. Apelin is an adipokine that elicits endothelium-dependent vasorelaxation and reduces arterial blood pressure, while relaxin is a protein hormone that induces the production of nitric oxide and vascular endothelial growth factor and inhibits endothelin and angiotensin II. This study aimed to investigate whether apelin and relaxin plasma levels are affected in patients with MH and compare the findings with those of healthy normotensives. One hundred-thirty (60 men, 70 women) healthy patients with a mean age of 45±12 years who had clinic blood pressure <140/90 mmHg were studied. The whole study population underwent 24-hour ambulatory blood pressure monitoring (ABPM). According to the ABPM recordings, 24 individuals (8 men, 16 women) had MH and the remaining 106 patients (52 men, 54 women) had normal ABPM recordings. Apelin and relaxin plasma levels were determined in both groups (enzyme-linked immunosorbent assay method). The apelin (220±121 vs 315±147 pg/mL, P=.001) and relaxin (35.2±6.7 vs 56.8±13.6 pg/mL, P<.001) plasma levels were significantly lower in the masked hypertensive group compared with normotensive controls. Our findings suggest that patients with masked hypertension have significantly lower apelin and relaxin levels. This observation may have prognostic significance for future cardiovascular events in patients with MH and needs further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.